NEW YORK ( TheStreet) -- Cynosure (Nasdaq: CYNO) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.

Cynosure, Inc. develops and markets aesthetic treatment systems to the dermatology, plastic surgery, and general medical markets. Cynosure has a market cap of $115.5 million and is part of the health care sector and health services industry. Shares are up 33.7% year to date as of the close of trading on Tuesday.

You can view the full Cynosure Ratings Report or get investment ideas from our investment research center.

If you liked this article you might like

Medtronic Earnings Rebound in Third Quarter, Shares Climb

Deals of the Week: Valentine Couplings and Breakups

Wall Street Smashes Records for Fourth Day in a Row After Rocky Session

Stocks Find Upward Momentum Again as Chances of a Rate Hike Rise

Stocks Mixed as Fed's Yellen Talks Rates on Capitol Hill